ImpediMed Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ImpediMed wird ein jährliches Gewinn- und Umsatzwachstum von 49.7% bzw. 39.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 55.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -11.9% betragen.

Wichtige Informationen

49.7%

Wachstumsrate der Gewinne

55.3%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	39.8%
Zukünftige Eigenkapitalrendite	-11.9%
Analystenabdeckung	Low
Zuletzt aktualisiert	01 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Aug 25

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Apr 06

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

Feb 12

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Jan 08

Gewinn- und Umsatzwachstumsprognosen

ASX:IPD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2026	32	-2	-1	2	1
6/30/2025	19	-14	-17	-13	2
6/30/2024	11	-21	-23	-18	2
12/31/2023	10	-19	-18	-13	N/A
9/30/2023	11	-20	-21	-15	N/A
6/30/2023	11	-21	-24	-18	N/A
3/31/2023	11	-21	-25	-20	N/A
12/31/2022	11	-22	-27	-22	N/A
9/30/2022	11	-21	-24	-19	N/A
6/30/2022	11	-20	-21	-16	N/A
3/31/2022	10	-20	-19	-14	N/A
12/31/2021	10	-19	-17	-13	N/A
9/30/2021	9	-20	-16	-13	N/A
6/30/2021	8	-21	-16	-13	N/A
3/31/2021	7	-20	-17	-15	N/A
12/31/2020	6	-19	-18	-16	N/A
9/30/2020	6	-20	-20	-18	N/A
6/30/2020	6	-21	-21	-19	N/A
12/31/2019	5	-25	-22	-20	N/A
9/30/2019	5	-24	-22	-20	N/A
6/30/2019	4	-24	-22	-20	N/A
12/31/2018	4	-25	-23	-21	N/A
9/30/2018	3	-26	-24	-22	N/A
6/30/2018	3	-27	-25	-23	N/A
3/31/2018	4	-28	N/A	N/A	N/A
12/31/2017	4	-28	-26	-26	N/A
9/30/2017	5	-28	N/A	-26	N/A
6/30/2017	6	-28	N/A	-26	N/A
3/31/2017	6	-28	N/A	-25	N/A
12/31/2016	6	-29	N/A	-25	N/A
9/30/2016	6	-27	N/A	-24	N/A
6/30/2016	6	-26	N/A	-22	N/A
3/31/2016	6	-23	N/A	-19	N/A
12/31/2015	5	-20	N/A	-16	N/A
9/30/2015	5	-17	N/A	-13	N/A
6/30/2015	5	-15	N/A	-11	N/A
3/31/2015	4	-13	N/A	-9	N/A
12/31/2014	4	-10	N/A	-8	N/A
9/30/2014	4	-9	N/A	-7	N/A
6/30/2014	4	-8	N/A	-7	N/A
3/31/2014	3	-7	N/A	-6	N/A
12/31/2013	3	-7	N/A	-6	N/A
9/30/2013	3	-8	N/A	-7	N/A
6/30/2013	3	-8	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IPD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IPD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IPD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IPDDie Einnahmen des Unternehmens (39.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Australian (4.9% pro Jahr).

Hohe Wachstumseinnahmen: IPDDie Einnahmen des Unternehmens (39.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: IPD wird voraussichtlich in 3 Jahren unrentabel sein.

ImpediMed Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 9.6% to AU$0.18

Consensus revenue estimates decrease by 13%

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

Consensus revenue estimates decrease by 20%

Price target decreased by 16% to AU$0.23

Recent updates

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

New minor risk - Market cap size

Independent Non-Executive Director recently bought AU$50k worth of stock

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates decrease by 13%

Independent Non-Executive Director recently bought AU$90k worth of stock

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

High number of new and inexperienced directors

New minor risk - Share price stability

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Consensus revenue estimates decrease by 20%

ImpediMed Limited Announces CFO Changes

Price target decreased by 16% to AU$0.23

Price target increased by 21% to AU$0.27

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Consensus revenue estimates decrease by 23%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

Price target increased by 27% to AU$0.21

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ImpediMed Limited, Annual General Meeting, Oct 26, 2022

Price target decreased to AU$0.22

ImpediMed Limited Announces Executive Changes

Less than half of directors are independent

ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform

No longer forecast to breakeven

ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022

ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up